The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the ...

People with Dravet syndrome experience intractable seizures throughout their lives — seizures that usually begin before they are 1 year old. What’s more, these seizures aren’t all of the ...

Dravet syndrome is a type of epilepsy that starts during a child's first year. If your child has this condition, they might have seizures that last for several minutes at a time.

Dravet syndrome is a rare, severe form of epilepsy with symptoms that begin before a child turns 15 months old (and often within the first year of life). (1) Formerly known as severe myoclonic ...

Because Dravet syndrome is a rare, complex medical disease that is lifelong, it’s important for families to find comprehensive care.

As heatwaves become more intense with climate change, scientists are racing to understand how extreme heat changes the way ...

Treatment Arms: Patients in the active treatment arm will receive two 70mg loading doses (Day 1 and Week 8) followed by two 45mg maintenance doses (Week 24 and Week 40). All patients will continue to ...

Grace has Dravet syndrome, a rare and severe form of epilepsy that usually begins within the first year of life. A 2015 study estimates the condition affects up to 1 in 16,000 infants born in the ...